Link to this page
Experimental Conditions Ontology
Last uploaded:
January 13, 2025
Jump to:
| Preferred Name | canagliflozin | |
| Synonyms |
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol canagliflozin anhydrous |
|
| Definitions |
This is any condition in which the main influencing factor is canagliflozin, a glucoside-derived sodium/glucose cotransporter (Slc5a2) inhibitor used clinically to treat type 2 diabetes mellitus. |
|
| ID |
http://purl.obolibrary.org/obo/XCO_0001433 |
|
| created_by |
slaulederkind
|
|
| creation_date |
2024-07-08T16:47:06Z
|
|
| database_cross_reference |
CHEBI:73274 CID:24812758
|
|
| definition |
This is any condition in which the main influencing factor is canagliflozin, a glucoside-derived sodium/glucose cotransporter (Slc5a2) inhibitor used clinically to treat type 2 diabetes mellitus.
|
|
| has_exact_synonym |
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol canagliflozin anhydrous
|
|
| has_obo_namespace |
experimental_condition_ontology
|
|
| id |
XCO:0001433
|
|
| label |
canagliflozin
|
|
| notation |
XCO:0001433
|
|
| prefLabel |
canagliflozin
|
|
| treeView | ||
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping